As this year’s ERS meeting is about to kick off, we’ve looked back at the last three years at TherapeutAix and the 20 projects we have supported in the respiratory space.
Most of these projects have been in pulmonary fibrosis, but there were also projects targeting COPD and other pulmonary indications. Our work in the respiratory therapeutic area is broken down as follows:
- IPF – 16 projects
- Inhaled – 9 projects (5 of which have been in the last year)
- COPD – 3 projects
- Other – 1 project
We believe that a sound development program should start with the end in mind and a clear aspiration of a treatment setting. This allows to design development programs be based on human cell assays, mechanistic forward translation, and learnings from existing clinical data (backtranslation). We’ve published some of our thoughts a few months back in Drug Discovery Today which focused on the challenges and opportunities of drug development in IPF, and two approved drugs, pirfenidone and nintedanib.
Targeted therapies – Inhalation
We are also excited to see an increasing number of projects with locally targeted therapy, which mostly is achieved via inhalation. This approach comes with unique benefits, such as reduced systemic side effects, but also presents challenges that need to be considered early in the development program, including a general hesitancy from the pharma and investor community. We’ve discussed all this and more in our blog series earlier this year.
Read our four-part series on idiopathic pulmonary fibrosis (IPF):
As part of the TherapeutAix Approach, we offer an initial review of your project, completely free of charge so that we can access the project and see how we can work together. This gives you a chance to get to know us and understand how we can aid your project, at no expense or risk to you.
Here is some great feedback we received last week following our free advice on an inhalation project:
‘Thanks again for your initial feedback. I can see that some of the points you have raised will be incredibly useful for us to consider now (really great free advice as you foreshadowed).’
Find out more about how we work here.
We’d be happy to discuss these approaches further, and what this could mean for your project. If this sounds interesting – but also if you just want to say hello – please get in touch! Together we can help more medicines reach patients.
The ERS Congress
The ERS International Congress 2021 is taking place virtually from 5-8 September. The annual congress brings together the world’s respiratory experts, to present and discuss the latest scientific and clinical advances across the entire field of respiratory medicine.
We would love to introduce our unique approach to project review, strategy and networked R&D, and discuss how we can help you with your project. If you are attending the ERS Congress and would like to know more, please get in touch via email@example.com and we will be happy to arrange a virtual coffee meeting with you.
You can access the ERS Congress online platform here.